Innate Pharma (IPHA) Shares Outstanding (2017 - 2025)
Innate Pharma's (IPHA) quarterly Shares Outstanding (Entity) came in at $90.0 in Q4 2025, up 11.11% YoY from $81.0 in Q4 2024, and up 3.45% on a QoQ basis from $87.0 in Q2 2025.
Innate Pharma (IPHA) Shares Outstanding (2017 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 9 years of Shares Outstanding (Entity) data on file, last reported at $90.0 in Q4 2025.
- Quarterly Shares Outstanding (Entity) rose 11.11% year-over-year to $90.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $90.0 (up 11.11% YoY) and the FY2025 annual result came in at $90.0, up 11.11% from the prior year.
- Shares Outstanding (Entity) improved to $90.0 in Q4 2025, from $87.0 in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $90.0 in Q4 2025 to a low of $79.0 in Q2 2021.
- A 5-year average of $81.8 and a median of $80.0 in 2021 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2021 — Shares Outstanding (Entity) changed 0.0% — and 2025, when it grew 11.11%.
- Tracing IPHA's Shares Outstanding (Entity) over 5 years: stood at $80.0 in 2021, then changed by 0.0% to $80.0 in 2022, then changed by 0.0% to $80.0 in 2023, then rose by 1.25% to $81.0 in 2024, then rose by 11.11% to $90.0 in 2025.
- The last three Shares Outstanding (Entity) figures came in at $90.0 (Q4 2025), $87.0 (Q2 2025), and $81.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.89 Bn | 131.04 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 86.05 Bn | 78.06 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 65.56 Bn | 60.38 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 55.46 Bn | 50.32 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.30 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 445.06 Mn |
| 10 | Innate Pharma | 199.79 Mn | 199.79 Mn | - | 89.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 89.59 Mn |
| Jun 30, 2025 | 86.94 Mn |
| Dec 31, 2024 | 81.05 Mn |
| Jun 30, 2024 | 80.87 Mn |
| Dec 31, 2023 | 80.45 Mn |
| Jun 30, 2023 | 80.32 Mn |
| Dec 31, 2022 | 79.64 Mn |
| Jun 30, 2022 | 79.75 Mn |
| Dec 31, 2021 | 79.54 Mn |
| Jun 30, 2021 | 79.00 Mn |
| Dec 31, 2020 | 78.93 Mn |
| Jun 30, 2020 | 78.89 Mn |
| Dec 31, 2019 | 66.91 Mn |
| Jun 30, 2019 | 63.99 Mn |
| Dec 31, 2018 | 58.78 Mn |
| Dec 31, 2017 | 54.35 Mn |